FDC Limited

₹392.60As of Sun 8 Nov 2026, 12:00 UTC

NSE:FDCHealthcare

Country India

PE (Fwd) 20.00

TSR 10Y CAGR 6.02%

Div yield 1.27%

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.11

PE TTM 22.71

TSR TTM (13.69%)

Mkt cap ₹64.31B

ROIC —

SE Grade™

Value

Quality

Moat

—

1Y Price

Reference

₹429

9.28%

(63.69%)

Price above Reference Value

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

21.71

Revenue₹B

—

15.28

17.84

19.43

21.08

21.71

23.32

9.18%

2.98

Revenue growth%

—

16.74

8.92

8.50

2.98

7.42

8.71

—

65.75

Gross margin%

—

63.50

61.36

64.45

63.32

65.75

65.68

63.50

13.21

Operating margin%

—

14.16

11.89

15.37

12.86

13.21

13.14

13.21

12.96

Net margin%

—

14.16

10.88

15.71

12.66

12.96

12.86

12.96

22.71

P/E ratio (avg)x

—

25.40

23.60

20.08

31.21

25.24

21.31

25.24

22.28

EV/EBITx

—

25.40

21.60

20.53

30.72

24.76

20.86

24.76

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

17.29

EPS₹

—

12.82

11.67

18.59

16.39

17.29

18.42

7.76%

—

5.49

EPS growth%

—

(8.94)

59.22

(11.84)

5.49

6.57

(1.73)

—

Bookvalue per sh₹

—

FCF per share₹

—

5.00

Dividend per sh₹

—

5.00

5.51

—

1.27

Div yield (avg)%

—

0.98

1.15

1.40

1.06

—

28.93

Payout ratio%

—

30.51

28.93

29.92

—

162.8

Shares (diluted)M

—

168.8

166.2

164.2

162.8

◌162.8

(0.90%)

—

Buyback yield%

—

1.53

1.21

0.86

—

◌—

1.03

—

D/E ratiox

—

63.92

Enterprise value₹B

—

54.97

45.79

61.30

83.26

71.03

63.92

6.62%

—

LT debt₹M

—

Peers (US$676.6M)

Cap (US$)

Bliss GVS Pharma…

684.0M

48.73x

Sun Pharma Advanced…

669.6M

3.849x

Innova Captab Limited

623.6M

38.02x

Hunan Fangsheng…

677.9M

13.74x

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

68.30

72.61

Own earn%

—

Sh yield%

1.27

1.37

Owners

Insiders/Inst%

48.03

7.24

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

5/5

Revenue growth years

4/4

EPS growth years

2/4

Dividend streakyrs

Op margin range%

12–15

$1 testx

—

Incr. ROIC%

—

FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹21.71B

9.18%

1.00×

Cost of revenue

₹7.436B

7.46%

0.94×

Operating expenses

₹11.40B

10.90%

1.06×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m